| Status | In progress |
| Process | STA 2018 |
| ID number | 1589 |
Provisional Schedule
| Committee meeting: 1 | 14 July 2020 |
| Expected publication | 23 September 2020 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TAcommA@nice.org.uk
| Evidence Review Group / Assessment Group | Health Economics Research Unit and Health Services Research Unit, University of Aberdeen |
Consultees
| Companies sponsors | Recordati Rare Diseases UK |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Lymphoma Action |
| Professional groups | British Association of Dermatologists |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists |
Commentators
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2019 | Invitation to participate |
| 06 August 2019 - 04 September 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 08 May 2019 | In progress. Referred 18 March 2019 |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance